logo-loader
MiningPotash & fertilisers
Sirius Minerals PLC

Sirius Minerals puts long running finance negotiations on hold as new funding proposal lands

“The company believes that the alternative proposal potentially offers a more flexible and attractive solution to its stage 2 financing requirements"

sirius minerals
The original route envisaged a US$3bn multi-tranche structure to fund the mine

Sirius Minerals PLC (LON:SXX) has put its long-running debt financing talks on hold as it has received a new alternative funding proposal.

The news sent Sirius shares soaring by 9.6% to 19.7p come Tuesday afternoon.

In a statement, the UK mine developer said the new proposal contains an alternative senior debt structure which would replace the structure envisaged in the prior negotiations, that began back in 2016.

READ: Sirius Minerals reveals its Yorkshire mine will rely less on government debt

“The company believes that the alternative proposal potentially offers a more flexible and attractive solution to its stage 2 financing requirements and therefore it is pausing discussions with its existing prospective lenders to pursue the alternative proposal,” Sirius said in a statement.

“A number of options for the additional non-senior debt financing requirement, as previously outlined in the company's announcement of 6 September 2018, continue to be progressed.”

Sirius told investors that it is working to obtain firm commitments for the new proposal and any additional financing before the end of April.

“We think this gives some clarity around the delays in debt financing from a top-down view looks a simpler solution with only one party to deal with,” said Liberum analysts Richard Knights, who repeated his ‘buy’ recommendation.

-Adds share price and analyst comment--

Quick facts: Sirius Minerals PLC

Price: £0.09

Market: LSE
Market Cap: £631.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

8 hours, 43 minutes ago

2 min read